Past and present perspectives on encapsulating peritoneal sclerosis.

Area of Science:

• Nephrology
• Gastroenterology
• Surgical Complications

Background:

• Encapsulating peritoneal sclerosis (EPS) is a severe complication associated with long-term peritoneal dialysis.
• Historically, EPS carried a high mortality rate, mainly due to bowel obstruction.
• Recent research has elucidated EPS pathogenesis, disease progression, and treatment protocols.

Purpose of the Study:

• To review the current understanding of Encapsulating peritoneal sclerosis (EPS).
• To outline established treatment strategies and risk reduction measures for EPS.
• To highlight the improved prognosis of EPS due to recent advancements.

Main Methods:

• Review of clinical research on Encapsulating peritoneal sclerosis (EPS) pathogenesis and clinical course.
• Analysis of current therapeutic consensus, including corticosteroids, tamoxifen, and surgical enterolysis.
• Evaluation of the impact of biocompatible peritoneal dialysis solutions on EPS risk.

Main Results:

• Established consensus on timely treatment with corticosteroids and tamoxifen for EPS.
• Surgical enterolysis (adhesiolysis) remains a definitive treatment option for advanced EPS.
• Introduction of biocompatible peritoneal dialysis solutions may reduce peritoneal deterioration and EPS incidence.

Conclusions:

• Encapsulating peritoneal sclerosis (EPS) is no longer considered a fatal complication of peritoneal dialysis.
• A multi-faceted approach involving timely medical and surgical interventions, alongside improved dialysis solutions, has transformed EPS outcomes.
• Continued research and clinical practice have led to effective countermeasures against EPS.